NCT03748810View on ClinicalTrials.gov

Head-to-head Comparison of Empagliflozin and Dapagliflozin

CompletedOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Type2 Diabetes
Interventions
DRUG

Empagliflozin

Empagliflozin 25 mg once daily add on the background OADs for 3 years

DRUG

Dapagliflozin

Dapagliflozin 25 mg once daily add on the background OADs for 3 years

Trial Locations (1)

28644

Chungbuk National University Hospital, Cheonju

All Listed Sponsors
lead

Chungbuk National University Hospital

OTHER

NCT03748810 - Head-to-head Comparison of Empagliflozin and Dapagliflozin | Biotech Hunter | Biotech Hunter